Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

About this update from Callan Jmb Inc.

GALVESTON, TX / ACCESS Newswire / January 12, 2026 / Callan JMB Inc. (NASDAQ:CJMB) , a premier provider of vertically integrated temperature-controlled logistics and specialized life sciences fulfillment, today announced a comprehensive strategic realignment to address the critical infrastructure gap in the global distribution of GLP-1 (glucagon-like peptide-1) medications. As the pharmaceutical industry faces a logistics bottleneck due to the meteoric rise of weight-management and diabetes treatments such as Ozempic®, Wegovy®, and Mounjaro®, Callan JMB is positioning its proprietary cold-chain technology to become the primary "last-mile" fulfillment partner for large-scale telehealth and pharmaceutical distributors. Expanding the Cold-Chain Frontier The distribution of GLP-1 agonists requires an unbroken cold chain between 2°C and 8°C (35.6°F to 46.4°F). Any deviation renders these high-value biological drugs ineffective. Callan JMB's strategic expansion includes: A $100 Billion Market Opportunity "The pharmaceutical industry is at a crossroads. The demand for GLP-1 therapies is projected to exceed $100 billion by 2030, yet the infrastructure to move these drugs safely is severely undersized," stated Wayne D. Williams, CEO of Callan JMB . "By leveraging our expertise in emergency preparedness and regulated materials, we are capturing a first-mover advantage in the GLP-1 logistics space . We are building the specialized 'pipes' through which the future of metabolic medicine will flow." Financial and Operational Resilience This strategic pivot is backed by a robust balance sheet and stable recurring revenue from long-term government contracts, including the recently extended $9.1 million agreement with the City of Chicago. The company's lean capital structure and recent insider accumulation underscore management's confidence in this new growth vertical. The Valuation Arbitrage: Transitioning from Logistics to a High-Margin CDMO Player The market currently values $CJMB as a "micro-cap shipping company." This is a massive mistake. If you look at the recent agreement to host specialized oral drug delivery manufacturing equipment in their Texas facility, the company is fundamentally shifting its business model. Name: Klaas Wijnands Company: Vortex Finance Email: [email protected] Phone: 633700754 SOURCE: Callan JMB Inc. View the original press release on ACCESS Newswire

View stock analysis, news, and events for Callan Jmb Inc.